NCT00333502 - Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

November 30, 2011

Study Completion Date

April 30, 2012

Conditions

CancerSolid Tumor

Interventions

DRUG

Camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer

Subjects who meet inclusion/exclusion criteria will receive CRLX101 every other week.

Trial Locations (3)

Virginia G. Piper Cancer Center, Scottsdale

San Juan Oncology Associates, Farmington

City of Hope National Medical Center, Duarte